Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

Third, chemotherapy given as part of concurrent chemoradiation may act systemically and potentially eradicate distant micrometastases.

With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...

The advent of concurrent chemoradiation has significantly contributed to the curability of head and neck cancer, including locoregionally advanced disease. Preserving organ function and reducing ...

AstraZeneca Pharma India gets CDSCO nod for durvalumab to treat LS-SCLC: Our Bureau, Bengaluru Monday, March 10, 2025, 15:30 Hrs [IST] AstraZeneca Pharma India, received a Central ...

Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Oral cancer is a type of head and neck cancer that develops when abnormal cells within the lining of the cheeks, gums, roof of the mouth, tongue, or lips grow uncontrollably. Oftentimes, oropharyngeal ...